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Quantitative indices of clinical uremia. The disabling, dialysis-
responsive symptoms of clinical uremia primarily represent im-
paired functions of the nervous system. Accordingly, these stud-
ies used several quantitative electrophysiologic and cognition-
dependent probes of nervous system function: peripheral nerve-
conduction velocity, response latency and amplitude; electroen-
cephalographic (EEG) power-spectrum analysis; visual evoked
response latency; EEG responses to photic driving; and mea-
sures of integrated behavioral performance that stressed sus-
tained and selective attention, reaction time, speed of decision-
making, short-term memory, and mental manipulation of sym-
bols. Probes of quantified central nervous system function con-
sistently revealed impairments that varied directly with the de-
gree of renal failure, that improved following onset of mainte-
nance dialysis, and that improved still further after successful
renal transplantation. In contrast, measures of peripheral nerve
function were generally unchanged. Neurobehavioral measures
that are relevant to uremic symptomatology provide quan-
titative estimates of the clinically significant, whole-organism bi-
ologic effects of renal failure and its several treatments. Appli-
cations of such measures in studies of symptomatic states other
than uremia are indicated also.
Indices quantitatifs de l'urémie clinique. Les symptômes invali-
dants de l'urémie clinique qui peuvent être améliorés par la
dialyse traduisent essentiellement l'altération des fonctions
du système nerveux. De ce fait, les etudes rapportëes ont utilisé
diverses explorations quantitatives, électrophysiologiques et
cognitives, des fonctions du système nerveux: vitesse de con-
duction des nerfs pCriphdriques, latence et amplitude de Ia ré-
ponse; analyse du spectre de puissance de l'EEG; latence de
la réponse évoquée visuelle; réponses EEG a la stimulation
lumineuse; mesures de performances comportementales intCgrees
qui impliquent le soutien, et Ia sélectivité de l'attention, le temps
de reaction, Ia vitesse de decision, la mémoire a court terme,
et la manipulation de symboles. L'Cvaluation quantitative des
fonctions do système nerveux central rdvèle constamment des
alterations qui varient dans le méme sens que le niveau d'insuf-
fisance rénale, qui sont améliorées après l'initiation de la
dialyse et encore plus améliorées aprés une transplantation
rCnale efficace. L'évaluation de Ia fonction nerveuse périphé-
rique, au contraire, n'est pas modifiée dans l'ensemble. Les
evaluations qui se rapportent a Ia symptomatologie uremique
perrnettent one estimation quantitative des effets de l'insuffisance
rénale et de ses différents traitements. L'utilisation de telles
mesures a des situations autres que l'urémie est aussi mdi-
quée.
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The symptoms which characterize and identify
the disabling clinical uremic illness in patients with
severe renal failure include mental sluggishness, di-
minished mental acuity and vigilance, drowsiness,
stupor, coma, irritability, restlessness, myoclonus,
and seizures, and anorexia, nausea, vomiting, itch-
ing, and hypothermia. These symptoms are mediat-
ed primarily by the nervous system and reflect cog-
nitive, somatosensory, neuromuscular, or autonom-
ic dysfunction.' They are improved and controlled
by adequate dialysis, and they improve further fol-
lowing successful renal transplantation. It seemed
logical therefore, that quantitative probes of ner-
vous system function might be used as whole-orga-
nism biologic "outcome measures" of the effects of
renal failure that are relevant to the generation of
uremic symptoms and their response to various
forms of therapy.
These investigations also derive from the fact that
the clinical uremic illness is identified by diverse
symptoms in patients, that is, in whole organisms,
rather than by abnormalities at such lower levels of
biologic organization as organs, tissues, cells, sub-
cellular biochemical processes, or in terms of the
molecular or ionic composition of biologic fluids [1].
Accordingly, to investigate clinical uremia and its
therapies with improved precision, we have (a) as-
In contrast, other systemic metabolic abnormalities that at-
tend renal failure and are conventionally implied by the term
"uremia" are generally asymptomatic, unresponsive to dialysis,
and do not contribute to patients' functional disability in daily
living. Even so nonspecific a complaint as weakness or easy fa-
tigability, which could derive from anemia, for example, reaches
the conscious level and is expressed in behavior, that is, in a
function (output) of the nervous system. More germane in this
example, however, is the component of "weakness," which im-
proves following dialysis without a change in hematocrit. Thus,
in this presentation, we recognize the essential nature of" symp-
tomatic uremia," "clinical uremia," the "uremic illness," and
soon, as a neurobehavioral syndrome, a cluster of overt, essen-
tially neurobehavioral manifestations (see Discussion).
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sembled, modified, or developed measures of sever-
al nervous system functions, impairments of which
are reflected in the several uremic symptoms; and
(b) used these measures repetitively in normal sub-
jects and in patients with varying degrees of chronic
renal failure, both before and after beginning treat-
ment with maintenance dialysis and following suc-
cessful renal transplantation. The validity and relia-
bility of the test measures themselves have been ex-
amined by standard methods.
These studies indicate that the measured, symp-
tom-related, neurobehavioral impairments vary di-
rectly with the degree of renal failure, improve with
maintenance dialysis treatment, and improve fur-
ther with successful renal transplantation, in paral-
lel with patients' symptoms of clinical uremia. This
parallelism, in turn, suggests the use of such quan-
titative measures to assess objectively the com-
parative adequacy of various treatment regimens,
specifically because these measures relate to the
clinical, symptomatic disability that severe renal
failure produces and for which dialysis and trans-
plantation are specifically used to modify and con-
trol.
Methods
Patients. Data were obtained from 132 patients
and 45 normal subjects. Of the 132 patients, 70 were
male (ages, 17 to 66 years), and 62 were female
(ages, 24 to 70 years). The major categories of
chronic renal disease were represented. All were
ambulatory outpatients with chronic renal failure
and were grouped in the following major categories:
Group 1. This group was composed of patients(N = 72) with varying severity of chronic renal fail-
ure, as indicated by serum creatinine concentra-
tions from 2 to 29 mg/dl, but not treated by means of
dialysis when the data were obtained. Data from
these patients are designated by "A" or "azotem-
ic" in the text and figures. This group was further
subdivided for some of the analyses. Patients with
serum creatinine concentrations of less than 10 mgI
dl were designated "low azotemic"; and those
above 10 mgldl as "high axotemic." Serum creati-
nine concentration was chosen as a convenient in-
dex of the degree of renal failure in azotemic pa-
tients only. We do not imply that creatinine itself
contributes in any way to uremic toxicity. These
data served to answer the question: Do the neuro-
behavioral test measures vary with the degree of
renal failure?
Group 2. This group was composed of patients
(N = 77) treated with chronic maintenance hemo-
dialysis. Neurobehavioral measurements were ob-
tained immediately prior to scheduled outpatient
dialysis treatments. The data are designated as "D"
or "dialyzed" in the text or figures and relate to the
question: Do the neurobehavioral test measures re-
spond to dialysis treatment?
Group 3. This group was composed of patients
(N = 18) who had undergone renal transplantation.
The data are designated by "T" or "transplanted"
in both the text and the figures and are pertinent to
the question: Do the neurobehavioral test measures
reflect a difference between patients' neurobeha-
vioral function during maintenance dialysis treat-
ment and following transplantation?
Several patients contributed data to more than
one group. Thus, as azotemic ("A") patients ulti-
mately began treatment by means of dialysis or
transplantation, their data appear in the "D" and
"T" categories as appropriate. In addition, serial
measurements permitted longitudinal, intrapatient
comparisons. In this report, 11 azotemic patients
began dialysis, and 6 traversed all three groups. In
one, serial measurements obtained in-hospital
documented the consequences of a rejection epi-
3ode that was controlled by steroids and graft irra-
diation.
Patient and data exclusions. Patients were ex-
cluded from study if they were mentally retarded
(I.Q., less than 70), blind, color-blind, could under-
stand little or no English, had a documented history
of psychosis, hearing defects, or such central ner-
vous system (CNS) defects as seizure disorder,
mass lesions, cerebrovascular accidents, or prior,
sustained malignant hypertension.
Neurobehavioral testing was rescheduled in cas-
es of intercurrent illnesses that could impair atten-
tion or button-pushing responses (for example, res-
piratory illnesses, arm or hand injury including
shunt infection, uncontrolled hypertension, or se-
vere headache); medication for pain or sleep in
greater than usual dosages within 8 hours prior to
testing; other medication (for example, methyl-
dopa) that might modify cerebral neurotransmis-
sion, within 8 hours of testing; or loss of greater
than one third of the usual amount of sleep during
the night preceding study. Using these criteria, we
rescheduled approximately 20% of the testing ses-
sions. The effect of age on test results was recog-
nized and controlled, at least in part, by assuring an
age range among normal control subjects equivalent
to that of the patients and by primary reliance on
repeated, within-patient measurements at short in-
678 Teschan et al
tervals rather than on normative, intersubject, and
intergroup comparisons.
In addition, to assure that test data obtained with-
in the "D" and "T" treatment condition were rep-
resentative of each patient's steady-state level in his
treatment category, we excluded data obtained dur-
ing transition periods, for example, within 60 days
after a patient's first dialysis or 45 days following
successful renal transplantation.
Clinical management and dialysis. Major com-
ponents of the patients' basic clinical management
are summarized in Table 1.
Normal control subjects. In addition to the pa-
tients under investigation, electrophysiologic and
cognition-dependent performance data were ob-
tained from a population of normal individuals, in-
cluding members of patients' families, without renal
disease. Of the 45 normal control subjects tested, 27
were male and 18 were female; subjects ranged in
age from 12 to 65 years. Education ranged from 3 to
20 years of schooling. These group characteristics
were also representative of the patient population.
These individuals permitted us to determine the sta-
bility of the measures in terms of test-retest repeat-
ability in a group of clinically stable individuals
without renal disease. Thus, the test scores of the
normal subjects provided a basis of comparison
with the clinically ill renal patients in normative
comparisons.
Biochemistry. Standard, automated methods
were used in all instances to assess serum and uri-
nary chemical composition. Blood and urine sam-
ples were obtained at the time of neurobehavioral
study in most instances or within the previous 1 to 7
days in those instances where simultaneous deter-
minations were not available. In the case of dia-
lyzed patients, we routinely obtained blood samples
before the dialysis that ended the longest inter-
dialytic interval of the week.
Neurobehavioral measures. We chose measures
that had been previously applied in studies of ure-
mic patients or that appeared likely to reflect the
cognitive, somatosensory, and neuromuscular dys-
functions characteristic of the uremic state. They
are of three general types and are classified as fol-
lows in the subsequent sections of this paper: (1)
electrophysiologic measures of peripheral nerve
function (conduction velocity, distal latency, and
amplitude of muscle and nerve compound action
potentials); (2) electrophysiologic measures of CNS
function (the spontaneous EEG [power spectrum
analysis], visual evoked response [VER], photic
driving response [PD]; (3) cognition-dependent per-
formance measures of CNS function (trail-making
test [TMTI, auditory short-term memory [ASTM],
continuous memory test [CMT], answer recognition
[AR], choice reaction time [CR11, continuous per-
formance test [CPT]).
The following descriptions of neurobehavioral
methods are greatly abbreviated to conserve space,
Table 1. Summary of basic clinical management
Component
"A"
(azotemic,
no dialysis)
"D"
(maintenance
dialysis)
"T"
(posttransplant)
Dieta
Protein," g/kg 0.4 to 0.8 1.0 High protein (1.5 unless azotemic)
Calories, calories/kg 30 to 50 30 to 50 eals/kg 20 to 30 cals/kg; low CHO
Sodium,g 2 0.5to2 2inmostcases
Potassium, mEq 40 to 70 60 to 70 No restriction
Phosphate binder As needed to control As needed None
(aluminum gels) serum phosphate
Antihypertensive Diruetic and others
as needed
As needed As needed
Dialysis — Various dialyzers
3 x/weekc
—
Steroids (Prednisone), — Tapered to 10"
mg/day, p.o.
Immunosuppressives, — — 100 to 150
mg/day
a Adjusted to size of patient and individual needs. Supplemental iron and multivitamins are included.
b 60 to 80% as high biologic value protein.
Choice of dialyzers and dialysis time modified as needed according to rates of nitrogen accumulation, need for ultrafiltration, and size
of body water pool. QB approximated 200 mI/mm, Q 500 mI/mm in most patients. Predialysis BUN's varied between 70 and 120 mg/dl.d Incases of graft rejection, repeated doses of methylprednisolone, 500 mg i.v. were used; in one instance 150 rads were administered
times 4 to the graft to halt the rejection process.
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especially with respect to those measures that were
replaced by more useful formats in the course of
this work.2
Electrophysiologic measures of peripheral nerve function
Conduction velocity, distal latency and response
amplitude of the ulnar motor (UM; below elbow),
ulnar sensory (US) and peroneal motor (PM) nerve
were measured two to six (average, three) times per
patient at 6- to 12-month intervals in 72 patients.
The nerve conduction studies were performed ac-
cording to standard methods as described by Mayer
[2—4] except that only surface electrodes rather than
needle electrodes were used.
Electrophysiologic measures of CNS function
(1) The spontaneous EEG: (A) Recording meth-
odology. Five channels of EEG data were recorded
from electrodes located at P3, 01, and F3 in the In-
ternational 10 to 20 system of electrode placement
[5—8]. Since slow-wave activity due to uremic en-
cephalopathy is a generally diffuse phenomenon,
similar results could be obtained from any of the
electrode pairs; but to reduce time spent in analysis,
only records from the bipolar channel P3 to 01 were
quantified by means of computer analysis. The pos-
terior pair (P3 to 01) was chosen to minimize eye
movement artifacts and to allow recording of visual
evoked potentials. The right ear lobe served as
ground. Electrodes were held in place by means of
EC-2 electrode cream (Grass Instruments, 101 Old
Colony Avenue, Quincy, Massachusetts). Resis-
tance between electrodes was routinely less than
10,000 ohms.
EEG data were recorded simultaneously on a
Model 6, 8-channel Grass electroencephalograph
(gain = 71/2 tV/mm) and on a model-5600 Honey-
well tape recorder. A voice channel on the tape re-
corder was used to record pertinent data, with in-
dicator points made on the paper EEG record for
future reference. A minimum of 100 seconds of
EEG data was recorded for each analysis. The pa-
tient was asked to sit quietly with closed eyes and to
perform mental arithmetic. The latter cognitive ac-
tivity during the EEG recording was conducted to
avoid slow-wave activity due to sleep or drowsi-
ness. The technician recording the EEG was also
careful to instruct each patient to minimize move-
ments of the eyes and other muscles during the re-
cording.
2 Detailed descriptions of all methods are available on request
to the senior author.
(B) Spectral analysis methodology. EEG records
were quantified by computer sampling at 100 Hz
and performing a fast Fourier transform (FFT) on
each 5-second interval. Power spectra were ob-
tained from the FFT and displayed in Compressed
Spectral Array (CSA) format [9—12] in steps of 0.2
Hz, from 0.2 to 20.0 Hz. The CSA consists of verti-
cally stacked spectra obtained from temporally con-
tiguous 5-second epochs in the EEG. The utility of
the CSA lies in its simple visual presentation of the
time and frequency content in a compressed and
easily understood format. To quantify the relative
amount of slow-wave-related activity displayed in
CSA, we calculated the amount of power between 3
and 7 Hz, and we compared it to the power between
3 and 13 Hz. Spectral components below 3 Hz often
contained artifact-related activity, such as motion,
eye movement, sweating, or baseline sway arti-
facts. Therefore, the spectral power below 3 Hz
was eliminated from our estimates, whereas 13 Hz
was chosen as a practical boundary for an upper
limit that would include most measurable EEG
power, excluding sleep spindles. No attempt was
made to mimic the overall scoring of, or specific
pattern-recognition in, the multichannel EEG as
conducted visually by an electroencephalographer.
The EEG records, however, were controlled for
quality and freedom from artifacts and normal
drowsiness by an electroencephalographer. A study
of correspondence between visual and computer as-
sessments has been reported separately [13].
(2) Visual evoked response (VER). Visual evoked
responses [14] were elicited by a Grass PS-22 xenon
strobe placed 12 inches to the front and horizontal
to the patient's eyes and repetitively flashed for 100
seconds at 1 Hz. An intensity setting of 8 was used
for trials with the eyes open and an intensity of 16
trials with the eyes closed. The EEG was recorded
from 01-LM with an A2 (right ear lobe) ground. The
VER was extracted from the ongoing EEG by stan-
dard computer signal averaging technics applied
commutatively to the segments of the EEG follow-
ing each stimulus. Following averaging, a computer
program (Daquan Users Manual, Digital Equipment
Corporation, Software Services, Maynard, Massa-
chusetts) was used to detect maxima and minima in
the average waveform and to calculate the latency
of each peak in milliseconds. The latency of the
characteristic major negative deflection between 50
and 150 msec was selected as an endpoint measure.
(3) Photic driving response. Photic driving of the
EEG [15] was obtained by flashing the Grass PS-22
xenon strobe at an increasing rate, from 3 to 12 Hz
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Table 2. Performance measures of cognitive functions
Cognitive functions Operational definitions
Performance measures
TMT ASTM CMT AR CRT CPT
Sustained attention The ability to focus attention on a given task
for a period of time
X X X X X X
Selective attention The ability to respond only to relevant stimuli
among other extraneous and irrelevant stimuli
X
Speed of decision-making The ability to choose quickly from among two
or more alternative paths of action according
to some objective criteria
X X X X X
Short-term memory The ability to recognize or recite information
shortly after such material is presented
X X
Mental manipulation The ability to recognize or reconstruct the abstract X
of symbols associations between symbolic forms of language
Abbreviations are defined as TMT, trail making test [20-22]; ASTM, auditory short-term memory task [23]; CMT, continuous mem-
ory test (See Results); AR, answer recognition [24]; CRT, choice reaction time [25]; CPT, continuous performance test [26] (manufac-
tured by Henry Appleton, Boston University School of Medicine, 80 E. Concord Street, Boston, Massachusetts 02118).
for 10 seconds at each frequency without inter-
ruption between the successive steps. An intensity
setting of 8 was used with the patient's eyes open.
The EEG was analyzed very much like the resting
EEG, and CSAs of the photically driven EEG were
similarly plotted. Additional analyses were then
carried out on the spectral data matrix comprising
the CSA [16] to calculate the power in the funda-
mental frequency bandwidth and in its sub-
harmonics and superharmonics. The activity in the
fundamental and its superharmonics is inversely
correlated with the activity in the low frequency
range and in the subharmonics. Therefore a com-
posite measure of high and low activity was se-
lected as the ratio between the power in the sub-
harmonic band to the power in the fundamental
bandwidth.
Cognition-dependent performance measures
One of the major hypotheses that has guided our
research is that severe uremic conditions result in a
general loss of mental alertness, which is manifest-
ed in a variety of human performance variables.
Measures relating to various aspects of mental
alertness are discussed in Adams [17], Anastasi
[18], Buros [19], and other standard texts on psy-
chometric theory and practice. The cognitive func-
tions which are especially impaired in uremic pa-
tients are listed and briefly defined in Table 2 to-
gether with the performance measures relevant to
each which we have so far studied. Published meth-
ods for each of these measures are referenced in the
footnotes to Table 2.
Results
Measures of peripheral nerve function
The results are summarized in Table 3. None of
the measures of peripheral nerve function (nerve
conduction velocity, distal latency, or response am-
plitude) were significantly correlated with the de-
gree of renal failure as measured by the serum
creatinine concentration. Virtually all values fell
within generally accepted normal ranges [2-4]. Sim-
ilarly, only one of the nine measures revealed a sig-
nificant change following onset of hemodialysis: the
amplitude of the electromyographic response fol-
lowing the ulnar motor nerve stimulation (UM,
AMP) tended to decrease in 12 patients who had
determinations both in the A and in the D periods,
and also among 8 subjects before and after transit
between D and T status. Amplitude changes were
more variable in the other two nerves. Although
conduction velocity in peroneal nerves was found
to be at the lower limits of normal and sometimes
below in individual measurements, clinical neurop-
athy did not occur in these patients.
Electrophysiologic measures of central nervous system
function
The spontaneous EEG: Responses to renal fail-
ure, dialysis, and transplantation. Slow-wave-asso-
ciated power in the EEG, as reflected in the "per-
cent power" computation (3 to 7 Hz/3 to 13 Hz X
100), is correlated with the degree of renal failure as
indicated by serum creatinine concentration. Figure
1 shows the relationship between these variables for
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Table 3. Results of peripheral nerve function testsa
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Group "A"
(azotemic patients) Group "D" Group "T"
Correlations with serum Response to Response to renal
.
Peripheralnerve
function Measure5 Nerve
creatinine concentration hemodialysis treatment
—
transplantation
rwith CrC P' N - -XAC j P N - -x' XT5 P N
Axonal Conduction UM —0.14 NS 25 53.8 55.9 NS 12 54.3 56.8 NS 8
transmission velocity (CV),
msec
US
PM
—0.49 NS 10
—0.11 NS 22
50.0 57.8 NS 3
42.7 41.3 NS 10
— — —
38.7 41.4 NS
1
7
Neuromuscular Distal UM 0.27 NS 25 3.2 3.1 NS 12 3.2 3.2 NS 8
transmission: latency (DL), US —0.40 NS 11 2.9 3.0 NS 5 3.0 2.6 NS 2
rami, end- msec PM 0.16 NS 22 5.5 5.4 NS 10 5.6 5.4 NS 7
plates, cells Amplitude (A),
mV
jzV
mV
UM
US
PM
0.11 NS 25
0.47 NS 11
0.35 NS1 22
11.4 8.6 <0.001 12
22.0 26.9 NS 11
6.4 5.6 NS 22
10.5 8.6 <0.05
15.0 27.0 NS
4.2 2.8 NS
8
2
6
a Abbreviations are defined as: UM, ulnar motor nerve (below elbow); US, ulnar sensory nerve; PM, peroneal motor nerve; N, number
of subjects (= number of values)
b Normal values [2.-4]were: CV—UM: 59 [sD]5.5, range 47 to 73; US: 67.1 [sD]4.7; PM: 46.5 [sD]4.l, range 41 to 59. DL—UM:
2.7 [SD] 2.6, range 1.6 to 4.2; US: 2.4 (su)0.2, range 2.0 to 2.8; PM: 4.9 (sD)0.8, range 2.4 to 7.3. AMP—UM: 11.1 [sD]2.6,
range 5.6 to 20.0; PM: 7.3 [SD] 2.6, range 2.2 to 14.6.
Correlation, r, with creatinine. Range of serum concentrations was 2 to 20 mg/dl.
d Statistical significance of intrapatient comparisons [29—30].
Mean of the three values in azotemic patients just prior to onset of maintenance hemodialysis (A).
Mean of all values recorded following onset of maintenance hemodialysis (D) in the same patients who contributed the A values.
g Mean of all values obtained during maintenance hemodialysis treatment (D).
Mean of all values obtained following successful renal transplantation (T).
l 0.05 <P < 0.06.
the group of 56 undialyzed patients without prior
episodes of malignant hypertension (r = 0.63, P <
0.001).
The degree of slowing varies during individual
EEG records, and that variability, or dispersion, in-
creases with the level of azotemia. Thus, in the
same 56 records represented in Fig. 1, the standard
deviation of the power associated with slow wave
activity in successive 5-second intervals also varies
directly with the creatinine concentration among
azotemic patients without malignant hypertension(r = 0.49, P < 0.001). This finding confirms the visu-
ally observable effects in CSA plots as patients be-
High levels of power in the 3- to 7-Hz bandwidth at relatively
low concentrations of serum creatinine were sometimes found in
patients who previously sustained one or more episodes of malig-
nant hypertension [27]. Data from these patients were excluded
from this report. Milder and varying degrees of hypertension oc-
curred in virtually all patients, with correspondingly vigorous
antihypertensive therapy; but correlations among blood pres-
sure, drug therapy, and EEG normalities were riot evident by
inspection in the records. Ipsative (within-patient), detailed com-
parisons of specific drug effects upon the EEG were beyond the
scope of these studies. To these and the other similar figures,
each patient contributed a single data pair: the test result corre-
sponding to the highest creatinine concentration in the azotemic
period, so that the number of data pairs equals the number of
subjects.
r 0.63 r2 0.40
%P = 1.8 [Cr]+ 6.8
P<0.001
N =56
4 8 12 16 20 24
Serum creatirlirle concentration, mg/dI
Fig. 1. Percent slow-wave-associated (3 to 7 Hz)/(3 to 13 Hz)
EEG power vs. concurrent serum creatinine concentrations in 56
azotemic patients with chronic renal failure prior to onset of
maintenance hemodialysis.
80
70
60
come more azotemic [12, 27]. Thus, in addition to
numerical assessment of the CSA, inspection of the
CSA itself provided a rapid visual assessment of the
degree and variability of slowing occurring through-
out the entire single-channel EEG record. A clear
tendency toward increased slowing is evident as
serum creatinine concentrations increase [12].
.
50
40
30
20
10
0
0 28
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The effects of renal failure, dialysis, and trans-
plantation are illustrated in a single patient in Figs. 2
and 3. This 39-year-old, white, female patient had
end-stage renal failure due to chronic glomerulone-
phritis. Along with azotemia she developed sympto-
matic uremia, especially daytime drowsiness, in-
somnia, anorexia, nausea, some vomiting, and
weight loss. Prior to onset of maintenance dialysis,
slowing and dispersion of EEG power below 7 Hz
(37%) was evident. After a dialysis program was be-
gun, symptoms cleared, the BUN fell, and the EEG
normalized (11% power, 3 to 7 Hz/3 to 13 Hz). Re-
nal transplantation produced a small further im-
provement (to 6% power). On the sixth day after
transplantation, fever, declining urinary volume,
and increasing azotemia heralded transplant rejec-
tion. The BUN rose to 123 mg/dl under the influ-
ence of reduced renal function and high dose adre-
nal steroid therapy; and the EEG deteriorated (41%
power). At this point, a single hemodialysis im-
proved the EEG (to 14% power). The rejection pro-
cess subsided following increased doses of immuno-
suppressive therapy and graft irradiation; and again
slow-wave-associated power returned to the normal
range (6%), where it remained during 5 years'
follow-up. The EEG mean frequency and the maxi-
mum negative peak latency of the steady-state visu-
ally evoked cortical potential (VER) displayed simi-
lar variations but with differing magnitudes and time
constants. Discriminant analysis of these data have
also been reported [28].
In Fig. 4 are summarized the differences between
the EEG percent power (3 to 7 Hz/3 to 13 Hz) from
five groups of subjects: normals; "low" azotemic,
"high" azotemic, dialyzed, and transplanted pa-
tients. An analysis of variance (F = 7.32, P <
0.0001, df = 4,139) indicated that significant dif-
ferences existed between the group means. Clear
statistical differences (analysis of variance with
Duncan's a posteriori multiple comparison technic
[29]) between the low- and high-azotemic groups
confirm that EEGs from patients with more severe
A T
40
20Qr
LU
0
8.0
E
9.0U
100
>
90
80LU
>
70
150
100
50
20
C
10
a,
0
"Degree of freedom
1 2 3 4 5 7 8 9 10 11 12
Transplant
Time, months
Fig. 2. Response of neurobehavioral test measures in an individual patient to renal failure (A),
dialysis (D), renal transplantation, a transient episode of transplant rejection (R), and the post-
transplant period (PT). In the sixth month the successive data points were obtained on these
dates: April 1, 2,3,4,5, 8, and 23, corresponding to the CSA plots in Fig. 3. (See text; modified
from Fig. 4 [12].)
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4-01-74 73 6
4-02-74 75 18
4-02—74 — signs of transplant
rejection)
4-03-74 84 15
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renal failure demonstrate significantly more power
associated with slower EEG frequencies, as a
group. The ameliorating effects of dialysis are evi-
dent when data from high-azotemic patients and
dialyzed patients are compared, whereas EEG
slowing following renal transplantation is in-
distinguishable statistically from that in normal or
low-azotemic patients. Some of these between-
group differences reached statistical significance in
spite of the characteristically large and irrelevant in-
terpatient differences within each group.
The effects of maintenance dialysis and of trans-
plantation on slow-wave-associated EEG power are
shown most clearly, however, in data taken sequen-
tially from individual patients during their A, D,
and/or T status, respectively. The statistical be-
tween-treatment comparisons (analysis of variance
using randomized block design with subsampling
[30, 31]) eliminate the usually large and irrelevant
interpatient differences (Fig. 4). The improvement
(decrease) in EEG slowing when azotemic patients
are stabilized on maintenance dialysis treatment
Date BUN EEG % power
1—11—74 136 37
)1—15—74 — start maintenance dialysis)
3-05-74 78 11
)3—27-74 — renal transplant)
-___L
m=ZTTT
:=ff== -
-
4-04-74 98 29
4-05-74 123 41
)4-06-74 — one hernodialysis)
4-08-74 74 14
4-23-74 58 6
Fig. 3. GSA plots together with BUN and % EEG power data from the patient described in text
and Fig. 2 (modified from Fig. 3 [12]).
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Fig. 4. Slow-wave-associated EEG power in five clinical groups and in individuals contributing
data to more than one treatment group. In the group data, bars represent means (X) and brack-
ets SCM of the mean for the number (N) of individuals in the group. N = normals; Lo-A =
azotemia, serum creatinine < 10 mgldl; Hi-A = serum creatinine> 10 mg/dl; D = during stable
maintenance hemodialysis; T = following successful renal transplantation. For individuals con-
tributing data to more than one treatment situation (A, D, or T), each data point represents the
single value or the mean of 2 to 25 separate values from each patient in each treatment situation.
Open circles (0) identify four patients who traversed and were studied in all three clinical situa-
tions: A (Hi-A), D, and T. Levels of statistical significance (F) are shown for the indicated
comparisons: NS = not significant; (*) = P <0.05; (**) = P < 0.01.
and when dialyzed patients receive successful renal
transplants corresponds to the clinical improve-
ments noted after each transition by both the pa-
tients and their physicians.
Visual evoked response (VER): (A) Responses to
rena/failure, dialysis, and transplantation, Figure 5
depicts a typical normal VER, indicating the major
negative-peak latency that serves as the endpoint
measure. A significant correlation was demon-
strated between VER latency and serum creatinine
concentration as an index of renal failure in a range
of 1 to 20 mgldl in 48 azotemic patients not treated
by dialysis (r = 0.26, P < 0.05). In patients with
creatinine concentrations above 20 mgldl, the prom-
inent negative peak in the VER was often not clear-
ly identifiable.
Variations in VER peak latency in a single patient
before and after onset of maintenance dialysis and
during periods following renal transplant, transplant
rejection, and recovery are given in Fig. 2 together
with EEG and chemical data.
Figure 6 reveals differences in the average VER
latencies of 135 subjects without prior malignant hy-
pertension for the same five clinical categories as
described above for the spontaneous EEG (Fig. 4).
An analysis of variance of these data showed that
differences between groups were statistically signif-
icant at the P < 0.001 level. Differences in the VER
between the five groups were analyzed by the same
technics used in analysis of EEG power data and
were significant mainly in comparisons with nor-
mals, as shown. As expected, even higher levels of
statistical significance were achieved in within-pa-
tient comparisons of data from individual patients
before and after transition from azotemia to mainte-
nance dialysis, and from dialysis to posttransplant
status.
The statistically significant correlation with
creatinine as well as the normal versus low, and
high azotemia intergroup comparisons in Fig. 6 sug-
gest that VER latency is prolonged in direct relation
to the degree of renal failure. The loss of a clear
waveform at creatinine concentrations above 20
mgIlOO ml suggests that severe uremia greatly im-
pairs the normal encephalic response to photic stim-
ulation. Again, improvements following dialysis
50 A D
40
0 — I
30
H —A
17 28±2.0 21±1.5
23 27 48
MS * *
— * MS
20
16
NS
MS
*
MS
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Peak
latency, msec
100 rn-sec
Fig. 5. Normal visual evoked response (VER) elicited from EEG
(lead P3-01) by computer signal averaging. The major negative
peak latency is indicated.
and transplantation, which are seen in both group
and individual data, are consistent with observed
clinical changes in the patients.
(B) Photic driving. Figure 7 depicts CSAs of
photically driven EEGs recorded from a normal
subject and from a uremic patient. The character-
istic feature of the normal CSAs is the set of large
peaks marching across the time-frequency plane
and representing the EEG response to the flash
stimuli at the fundamental frequency of the xenon
light. To the right and below the peaks evoked by
the fundamental frequencies, the higher harmonics
(frequency = fundamental x 2, 3. . .) are clearly
discernible, whereas very little activity is noticed at
the low frequencies. The CSAs obtained from
photically-stimulated EEGs recorded from patients
with renal failure are clearly different. A large
Groups
amount of activity is noted above and to the left of
the fundamental frequency peaks, that is, in the low
frequency range; and less activity appears in the
fundamental or at the higher harmonic frequencies
[32].
When the total power in the subharmonic fre-
quencies (S) and that in the fundamental frequen-
cies (F) were quantified and expressed as a ratio
S/F, the latter correlated directly with the serum
creatinine concentration (r = 0.27, P < 0.05, N =
44). Figure 8 presents the data from five clinical
groups and from individuals who contributed data
during two or more treatment conditions.
Cognition-dependent performance measures of CNS
function
Trail-making test (TMT). TMT time recorded for
34 azotemic patients not receiving dialysis therapy
and without prior episodes of malignant hyper-
tension is statistically correlated with degree of re-
nal failure as indicated by serum creatinine levels (r
= 0.436, P < 0.01, N = 34). The mean TMT time of
the low-azotemic group is significantly shorter than
that of either the high azotemic group (P < 0.05) or
the dialysis group (P < 0.05). Even when test repe-
titions were separated by 6-month intervals, how-
ever, significant improvement in TMT performance
was observed across the first two test administra-
tions in both azotemic and dialyzed patients who
remained clinically and chemically stable between
Individuals
A D
FIg. 6. Visual evoked response (VER) latency in five clinical groups and in individuals contrib-
uting data to more than one treatment group. See legend to Fig. 4 for designations.
D —.T
120
100
80
N
D
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0246810 2 14 16 18 23 F
Frequency of EEG
Fig. 7. Compressed spectra! arrays showing responses of EEG
power spectrum (P3-01) to photic driving. Flash frequencies
were increased in 1-Hz steps sequentially from 3 to 12 Hz, and
maintained for 10 seconds at each step. Reprinted by permission
of Electroencephalogr Clin Neurophysiol [32].
tests (t = 2.71, P < 0.01, N = 25). Thus, despite the
diagnostic value of the TMT [33—38], it cannot be
administered on a repetitive basis over short time
intervals as required in these investigations.
Auditory short-term memory (ASTM). ASTM re-
sponse times of the normal controls were signifi-
cantly shorter than were those of the low-level azo-
temic patients (P < 0.05); the high azotemic group
60ci
(7
w
w
had significantly longer response times than did ei-
ther the low azotemic (P < 0.05) or the dialysis pa-
tients (P < 0.05). Every one of the six patients who
were administered the ASTM both before and after
beginning dialysis therapy demonstrated signifi-
cantly faster response times after the initiation of
dialysis. The test, however, could potentially mea-
sure either of two cognitive functions: speed of de-
cision or accuracy of short-term memory processes
[33—38]. In fact, most patients chose to respond
very accurately and hence differed in how rapidly
they could indicate their answer (response time).
This ambiguity in possible response strategy led us
to discontinue the ASTM in favor of the continuous
memory test, a short-term memory test not so de-
pendent on response time of so few responses.
Continuous memory test (CMT). The CMT is pri-
marily a measure of short-term recognition memo-
ry, with the successive words being presented in
such a way that sustained attention is necessary
[39]. A series of 110 words in five lists of 22 words
each were presented over a tape recorder via ear-
phones to the subject, whose task was to determine
whether or not each word had occurred previously
within the list. Each word was repeated after vary-
ing numbers of intervening words. The subject in-
dicated his answer, yes or no, by pressing the corre-
spondingly labeled switch. Although the speed of
U -—
x
A-D N
P
Normal subject
a)
E
I-
Groups Individuals
A 0
15
ic
40
0 — T
30
20
Lu-A H i-A
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5.8 .9 11.7 13.8 12.2 1.3
N 20 22 23 47
P: N
Lu-A
H i-A
D
— NS
7.4 .8
13
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-- NS
9.6 8.8
7 7
ii 8.5
D—T N 7
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Fig. 8. Ratio (S/F) of EEG power associated with the subharmonic (S) and fundamental (F)
frequencies in the photically-driven EEG, in five clinical groups and in individuals contributing
data to more than one treatment group. See legend to Fig. 4 for designations.
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Fig. 9. Continuous memory test scores (# errors) in five clinical groups and in individuals
contributing data to more than one treatment group. See legend to Fig. 4 for designations.
the subject's response was neither encouraged nor
recorded, it was necessary for him to respond with-
in the allocated 3-second interword interval. The to-
tal number of incorrect responses out of a possible
110 were recorded. Twelve test sets of 110 words
were used to eliminate a potential effect of learning.
CMT performance was statistically correlated with
the serum creatinine levels in 33 azotemic patients
not undergoing dialysis therapy (r = 0.392, P <
0.05, N = 33). CMT performance differed among
the patient groups (F = 4.01, P < 0.01, df = 4,117)
in that normal control subjects committed signifi-
cantly fewer errors than did either the high-level
azotemic group (P < 0.05) or the dialyzed patients
(P < 0.05) as shown in Fig. 9.
Answer recognition (AR) test. The AR test re-
quired the patient to decide the correctness of an-
swers to simple arithmetic problems [33—35, 38]. In
these studies, mean reaction time of AR was statis-
tically correlated with degree of renal failure in 23
azotemic patients not undergoing maintenance dial-
ysis (r = 0.560. P < 0.001). Among five patients
who were tested both before "A" and in "D," the
AR response times became shorter. AR test scores
appeared, however, to demonstrate a learning ef-
fect. In addition, different patients tended to use
quite different response strategies. Because these
factors could contribute to the variability of both
interpatient and intrapatient response times the AR
was dropped from the battery of performance mea-
sures.
Choice reaction time (CRT) test. The CRT is an
easily administered test, the scores directly reflect-
ing simple decision-making. The dependent variable
of concern is the mean reaction time derived from
the response times of the 24 test trials. A "learning
effect" was noted in a downward trend in scores of
the first three tests in virtually every patient. There-
after, the trend in scores did not differ significantly
from zero in normals or in stable patients. The CRT
scores obtained from the fourth and subsequent
tests were statistically correlated with the creati-
nine level of 21 azotemic patients under investiga-
tion (r = 0.438, P < 0.05, N = 21).
As indicated in Fig. 10, scores differed among the
clinical groups (F = 5.4, P < 0.001, df = 4,74). Post
hoc analyses [27] revealed that the normal controls
had significantly shorter response times than any
one of the three patient groups—low-level azotem-
ics (P < 0.05), high-level azotemics (P < 0.05), and
dialyzed patients (P < 0.05)—but that the response
times of transplant recipients did not differ statisti-
cally from the normals. Improvement was uniform
in intrapatient comparisons across treatments A—D
and D-T in individual patients (Fig. 10).
Comment. As reflected in the present data, the
CRT provides one of the most reliable indicants in
the present battery of performance tests of intra-
D —ø T
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patient change in renal failure [34, 37-39]. The cor-
relation coefficient of CRT versus creatinine con-
centration (r = 0.438) is, however, small, reflecting
interpatient differences in variables other than ure-
mia, which the CRT scores also reflect. For ex-
ample, the patient's age, independent of his degree
of renal failure, significantly contributes to his CRT
performance (r = 0.474, P < .025, N = 22). This
problem of individual differences, however, is in-
consequential when the CRT is used as an intra-
subject repeated measure, because variables such
as age remain essentially constant. Otherwise, pro-
ficiency on the CRT test is influenced little by other
idiosyncratic subject variables such as educational
level, verbal facility, and experiential factors, thus
making it a useful measure even among a heteroge-
nous patient population.
Continuous perfor,nance test (CPT). Proficiency
on the CPT appears to require sustained and selec-
tive attention in addition to rapid decision-making.
The CPT is a reaction time task of considerably
longer duration than the CRT (300 continuous tri-
als), which tended to make it more indicative of sus-
tained attention and vigilance [26, 39]. The percent-
age of errors recorded in the latest test session of
the "A" period from 26 azotemic patients not on
maintenance dialysis was statistically correlated
with serum creatinine concentration (r = 0.340, P <
0.05, N = 26).
As indicated in Fig. 11, the CPT scores of five
clinical groups were significantly different (F = 6.15,
P < 0.0003, df = 4.93). The normal controls had
a significantly smaller percentage of incorrect
responses than did either the low- or high-level azo-
temics (P < 0.05) or the dialyzed patients (P <
0.05). Response accuracy of the normal subjects did
not differ significantly from the transplant recipi-
ents; but the latter performed significantly better
than did either the azotemic groups or the dialyzed
patients. CPT proficiency improved following dial-
ysis treatment in two patients and after trans-
plantation in four of five patients for whom CPT
scores were obtained before and after each transi-
tion.
Discussion
Development of the concept. The concept that
neurobehavioral outputs can and should be mea-
sured as exquisitely relevant indices of the uremic
illness began in comprehensive studies of a model
of experimental acute renal failure in the rat [40-
45]. The relationships between renal failure and im-
paired cognition-dependent behavioral performance
were then explored further in Rhesus monkeys [46-
54], in which EEG slowing was also correlated with
behavioral output during progression of renal fail-
ure and treatment by means of peritoneal dialysis.
Fig. 10. Choice reaction time (seconds) in five clinical groups and in individuals contributing
data to more than one treatment group. See legend to Fig. 4 for designations.
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Viewed from this background of quantitative ex-
perimentation, both the classic and the modern de-
scriptions of disabling clinical uremia [35, 55—60]
necessarily lacked objectivity and precision, as is
the case with all verbal, narrative, and anecdotal
characterizations. Nevertheless, in these descrip-
tions, we recognized that the principal component
symptoms of the clinically overt uremic illness
share certain significant characteristics: (a) they oc-
cur in whole organisms, that is, at the highest level
of biological organization [1, 38, 61];(b) they reflect
impairments in one or more functions of the ner-
vous system: cognitive, neuromuscular, somato-
sensory and autonomic [27, 38, 62, 63]; (c) they dis-
able patients; and (d) they improve following dial-
ysis procedures.5
Likewise, the numerous biochemical abnormal-
ities, "chemical lesions," or "uremic toxins" de-
tected in "uremic" biological fluids by means of
proliferating laboratory methods lack a demon-
strated relevance to the clinically perceived illness-
behavior called "uremia" in patients with renal fail-
In striking contrast, the functional disorders of other organ sys-
tems which also occur in chronic renal failure (a) are not usually
detected in whole organisms but rather at such lower levels of
biological organization as organs, tissues, cells, and subcellular
biochemical transformations [1, 53]; (b) are generally asympto-
matic; (c) rarely disable patients; and (d) respond to an unknown
degree, sluggishly, or not at all to dialysis therapy [1].
ure or to its response to treatment by means of diet,
dialysis, or transplantation [I].
Accordingly, the concept is proposed, as illus-
trated in Fig. 12, that the nervous system provides a
linkage of relevance between the "chemical le-
sions," "uremic toxins," and abnormal metabolic
transactions of renal failure on one hand and the
"clinical, symptomatic lesions" of renal failure on
the other. Both electrophysiologic and psycho-
metric test measures estimate the symptom-related
neurobehavioral output in objective, quantitative
terms.
Current studies. The results of the present studies
like the experimental results cited initially in this
Discussion appear to validate the proposed con-
cept: that is, when the overt uremic illness is recog-
nized and investigated as a set of neurobehavioral
impairments, then, as expected, valid and reliable
measures of integrated nervous system function
quantitatively reflect such impairments and their
improvement following treatment [27, 33-36]. Thus,
the data vary in parallel with the patients' predicted
clinical responses, even when such responses are
"subclinical," that is, so subtle as to be inapparent
to the casual observer.
Moreover, the quantitative data obtained from
the spontaneous EEG, computer-averaged, evoked
cortical potentials, and six cognition-dependent
psychometric measures are strikingly similar in that
0
I—00
A D
x
Fig. 11. Continuousperformance test (% error) in five clinical groups and in individuals contrib-
uting data to more than one treatment group. See legend to Fig. 4 for designations.
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they uniformly vary together and often statistically
distinguish the major clinical situations of interest:
normals, renal failure of varying severity, treatment
by means of maintenance dialysis, the post-
transplant state, and also transitions between these
situations in individual examples [11—13, 28, 39,
64-65]. Similar findings were also reported by Spehr
et al [66].
The electroencephalogram. With respect to the
quantified EEG used in these studies, we emphasize
our limited application of computer technics only to
detect slowing in the 3- to 7-Hz frequency range and
dispersion of the frequency-related power spec-
trum, following the work of Kiley [67-72]. No at-
tempt was made to analyze for all EEG abnormal-
ities which have been described in uremic patients
[59, 63, 73-78]. Gross EEG abnormalities were rare
among the patients studied; and patients with
known seizure disorders were excluded at the out-
set. When assessments by computer and by an elec-
troencephalographer were compared, the degree of
correspondence was both satisfactory and instruc-
tive [13].
Electroencephalographic changes in acute renal
failure have been reported [79—80] to include in-
creased proportions of slow-wave frequencies as
the principal EEG abnormality detected by hand-
counting technics. The data reveal important simi-
larities to and differences from the present studies
of patients with chronic renal failure, including the
possible influences of parathyroid hormone and of
brain electrolytes, which are beyond the scope of
this discussion.
Visual evoked potentials and photic driving. The
visual evoked response (VER) was used in the pres-
ent studies as a probe for somatosensory dysfunc-
tion in uremia. The major negative peak latency
measured by computer signal-averaging technics
displayed responses to renal failure, dialysis, and
transplantation that were similar to, but more grad-
ual than were those of the EEG power spectrum
[64, 81, 82]. Analysis of photic driving responses
with increasing azotemia revealed increases in pow-
er associated with subharmonic frequencies, to-
gether with reciprocal decreases in power associat-
ed with the fundamental frequencies and the higher
order harmonics [36, 64]. Restoration of more nor-
mal patterns followed dialysis and transplantation.
Cognition-dependent performance measures.
Compared to EEG data, the probes involving in-
tegrated behavior in whole organisms may be more
apparently germane to several of the illness behav-
iors that characterize uremia in patients [37, 60].
Particularly important are those measures that test
for the cognitive dysfunction that appears early in
the course of progressive renal failure. Convention-
al criteria for validity and reliability were applied
(see Appendix.) The objective results in renal fail-
ure, dialysis, and following renal transplantation
generally paralleled both objective and subjective
clinical responses [33—35, 38]. Analagous findings
have been reported by others using other methods
[83—85].
Simple test procedures, of course, cannot be
equated with the entire repertoire of illness behav-
iors which clinicians perceive as the clinically-ap-
parent uremic syndrome. Cognitive dysfunction,
however, is an early and conspicuous element of
the abnormal, observed behaviors which comprise
the syndrome; and other elements may be examined
when appropriate, valid, and reliable measures are
developed.
Peripheral nerve function. As stated previously,
our studies failed to show significant changes in pe-
ripheral nerve conduction velocity in relation to the
levels of azotemia in undialyzed patients or in re-
sponse to treatment by means of dialysis or renal
transplantation. This result might have been ex-
Neurobehavioral probes
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Fig. 12. Relationships between quantified solute intake, output,
and residual concentration and the disabling dialysis- and
transplant-responsive symptoms of uremia. It is proposed that
neurobehayjoral measures that are relevant to uremic symptom-
atology provide quantitative estimates of the clinically signifi-
cant, whole-organism biologic effects of renal failure and its
several treatment modalities. [KT total solute removal rate =
Kr (residual renal clearance) + Kd (dialyzer clearance) + Kg(clearance via the gut)]. PCR = protein catabolic rate which
directly relates to the apparent generation rate (G) of urea and
presumably other solutes as well [99-102]. Contributions to
the body solute pool from the kidney, dialyzer and gut are in-
dicated in the dashed lines. Reprinted by permission of Dialysis
and Transplantation [108].
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pected, because the measurement reflects the func-
tion of the fastest remaining nerve fibers and hence
might remain relatively unchanged despite exten-
sive axonal damage in the course of uremic neurop-
athy [86]. Differences between these results and
those of others [87-95] may be explained by (a) on-
set of dialysis regimens earlier and at lower levels of
azotemia, that is, with still-significant levels of re-
sidual renal function [96]; (b) higher levels of dialy-
zer plus residual renal clearances; (c) measure-
ments on different nerves; and (d) use of different
equipment and possibly different measurement
technics [97-98]. Clinically significant neuropathy,
however, also did not occur in the patients studied
and rarely occurs in our nondiabetic patient popu-
lation. Other types of neuromuscular dysfunction
were not examined by any of the measures used.
We did not measure allegedly neurotoxic materials
in blood to relate these to either central or peripher-
al nerve function because such efforts were beyond
the scope of this investigation.
In contrast to the more "insulated" axons, the
fine neural rami, endplates, and muscle cell mem-
branes were anticipated to be more "exposed" to
the abnormal "uremic" environment, and hence
the distal latency and amplitude measures were an-
ticipated to reflect more sensitively effects of renal
failure and dialysis. The data, however, failed to re-
veal consistent changes, except for statistically sig-
nificant decreases during treatment with mainte-
nance dialysis or transplantation of the elec-
tromyographic potential amplitude following ulnar
motor nerve stimulation. This effect remains unex-
plained and also uncorrelated with our other mea-
surements of peripheral nerve function. We con-
clude that the measures of peripheral nerve function
used in these studies are much less sensitive than
are the other neurobehavioral measures to the ef-
fects of renal failure, dialysis, and transplantation,
and they appear to be both irrelevant and virtually
useless as indices of the dialysis-responsive uremic
illness.
Contributions to variance. Irrelevant inter-
individual differences were confounded in the ef-
fects of renal failure in the correlation analyses and
also in the analyses of variance of the group data. In
the correlation analyses, however, despite the irrel-
evant effect of individual uniqueness (low r and r2),
the effect of renal failure was still sufficiently con-
sistent to achieve a degree of statistical signifi-
cance. When the intersubject differences, however,
were eliminated in the between-treatment com-
parisons by the means of the statistical method of
randomized block design with subsampling [30-31],
intrasubject treatment effects achieved reasonably
high levels of statistical significance despite small
numbers of subjects (Figs. 4, 6, 8-11, "Individ-
uals").
Drug effects could have contributed to variance
in the data and were not studied separately. We
sought, however, to minimize such influences by
pretest screening (See Methods: Patient and data
exclusions). Similarly, parathyroid and other hor-
mone concentrations were not assayed in these
studies and could have contributed also to the ob-
served abnormalities [79, 80].
Limitations on variance. Variance in the data was
doubtless limited in these patients by our pretest
screening of patients as well as our preference for
beginning maintenance dialysis treatment in mini-
mally symptomatic patients. The florid "textbook"
uremic syndrome was not permitted in these pa-
tients: no EEG, for example, revealed the severe
abnormalities classically described as "character-
istic of uremia" [59, 63]. The measures themselves
apparently reflect phylogenetically fairly 'sturdy"
functions which need not be expected to deviate
greatly in the course of the relatively minor per-
turbations of renal failure that occurred in these
patients. More recent work, however, also suggests
that the measures used in these initial studies may
themselves be relatively insensitive as indicated by
their statistical reliability. (See Appendix Table.)
Potentially more sensitive measures are currently
being developed.
Implications for kinetically modeled dialysis, ra-
tionalized dialysis, alternative treatments of the
uremic syndrome, and for the relevance of various
nolecular species as "uremic toxins." The kinetic
relationships between intake, concentrations in
body fluids, and rates of removal by means of resid-
ual renal function and dialyzer clearance have been
quantified for small molecules like urea [98—102]
and estimated for somewhat larger ones ("middle
molecules") of unspecified chemical identity [90,
101, 103] (Fig. 12). It remains to be shown, how-
ever, that any of those solutes or those quan-
titations are relevant to the mainly neurobehavioral,
symptomatic, disabling clinical uremic illness.
Moreover, the serious attempts, for example by
means of chemical analytic methods, to "find the
uremic toxin" [1, 107] have been futile in the ab-
sence of (a) quantitative indices of the clinical ill-
ness that the chemical findings purportedly
"cause" and (b) definitive experiments that link the
chemical changes to the clinical indices quan-
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titatively. The present studies also provide no new
information on either the agents or the mechanisms
of dialysis- and transplant-responsive uremic tox-
icity.6 We have avoided, therefore, further futile
speculations about them.
Instead, we have presented the thesis and sup-
porting evidence that neurobehavioral measures are
conceptually relevant, quantitative indices of the
clinical uremic illness. As quantitative tools, they
may now be used experimentally to determine (a)
which of the chemical abnormalities of renal failure
are relevant to the overt, disabling, clinical uremic
illness and its response to treatment; and (b) which
diet, amino-, hydroxy-, or keto-acid supplement,
amount and mode of dialysis, or other means of so-
lute concentration control (for example, sorbents,
several modes of peritoneal dialysis, hemofiltration,
hemoperfusion) produces the optimal comparative
result in the prevention and control of such poten-
tially disabling uremic symptoms [1, 104—105].
General implications beyond renal failure and
uremia. In this work we recognized that the ner-
vous system receives exogenous and endogenous
stimuli (signals, information), synthesizes these
with stored memory, and, together with a greater or
lesser amount of conscious self-perception and
guidance to such processes, orchestrates" and ex-
ecutes observed behavior [38]. Thus, it is hardly
surprising that clinical uremia should mimic other
syndromes [62, 106-107] and vice versa, and that
objective, quantitative correlates of such integrated
behavioral responses to disease and its treatment
should be sought and used also in the study and
control of other clinical states which generate rec-
ognizable illness behavior.
Sunmar and conclusions. Disabling symptoms
of clinical uremia that respond to dialysis treatment
primarily represent nervous system dysfunction.
Therefore, to study the uremic illness and its re-
sponse to treatment objectively and systematically,
we used several electrophysiologic and cognition-
dependent probes of nervous system function. The
data consistently documented quantitative impair-
ments of CNS function that varied directly with the
degree of renal failure, improved following onset of
maintenance dialysis, and improved still further af-
ter successful renal transplantation. Concurrent
variations in the data in parallel with subjective
6 Specifically, we also do not interpret our data to implicate
creatinine as a neurotoxin but rather as in indirect index of the
degree of renal failure in azotemic patients before maintenance
dialysis is begun."
symptoms established the validity of the measures
used; and their reliability was demonstrated by con-
ventional statistical methods. In contrast, three
measures of peripheral nerve function showed little
systematic variation within or beyond the ranges of
normal values in the patients and circumstances
studied.
Within-subject comparisons of repeated mea-
sures in patients before and after transitions be-
tween azotemia, dialysis, and posttransplant status
usually revealed differences which were statistically
highly significant. These differences between treat-
ments were also often sufficiently great to achieve
statistical significance even in intergroup com-
parisons in which the generally large interpatient
differences might be expected to obscure the treat-
ment effect. Thus, several of the neurobehavioral
measures are presented as appropriate quantitative
dependent variables or endpoints by which certain
effects of such quantified independent variables as
the degree of renal failure and its treatments may be
objectively documented in terms which are relevant
to symptomatic uremia in patients.
It is reasonable to expect that experiments may
therefore become possible by which we may ex-
plore (a) the pathogenesis of uremic symptoms; (b)
the mechanisms of postdialysis improvement; (c)
how much dialysis is adequate; (d) rationalized de-
sign of dialyzers and related technics and in-
struments for control of body fluid composition;
and (e) rationalized alternative treatment other than
dialysis by which uremic symptoms may be con-
trolled. In each instance, the measures can provide
objective evidence of the response of the in-
tegrated, functioning whole organism to the disease
or the treatment, however relevant or irrelevant any
particular solutes and their loads, serum concentra-
tions, metabolism, and removal rates may be.
Neurobehavioral measures are also likely to be in-
creasingly useful in investigating clinical effects in
numerous disease states other than renal failure and
the clinically uremic state.
Appendix
Reliability and validity ofneurobehavioral measures. Because
the significance of our findings depends upon the reliability and
validity of the neurobehavioral measures themselves, the latter
have been subjected to critical analysis by generally accepted
statistical technics. Results of these assessments are given in the
Appendix Table and are elaborated as follows:
Before measures can be considered valid in any sense, they
must at least be reliable (relatively free from measurement er-
ror). Systematic investigations of test reliability usually require
hundreds of subjects (see discussion in Nunnally, 1967 [1091),
but of course this was not possible in our smaller clinical popu-
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Table 1 (Appendix). Reliability estimates of neurobehavioral measures8
Reliability criterion
Normalsubjects
E
]jb
EG
%power
VE
N"
R
msec
CR
N"
T
sec
CM
N"
T
%error
C
N"
PT
%error
Normal subjects 10(28) 10(30) 10(30) 11(33) 11(33)
Coefficientalpha[109] 0.974 NA 0.981 NA 0.977
Test-retest reliability coefficient [109] 0.86 0.88 0.75 0.74 0.93
Avg. within-subject coeff. of variation [116] 0.22 0.06 0.10 0.31 0.46
Dialyzed patients 15 (83) 15 (89) 15 (88) 14(77) 14(61)
Test-retest reliability coeff. 0.84 0.92 0.79 0.78 0.57
Avg. within-patient coeff. of variation 0.24 0.06 0.09 0.28 0.35
Posttransplant patients 8(38) 7(30) 8(40) 8(24) 8(17)
Test-retest reliability coeff. 0.89 0.75 0.66 0.50 0.78
Avg. within-patient coeff. of variation 0.38 0.09 0.13 0.47 0.31
a Abbreviations are defined as EEG, electroencephalogram; VER, visual evoked response; CRT, choice reaction time; CMT, continu-
ous memory test; CPT, continuous performance test.bN denotes number of subjects (number of observations). NA is not applicable.
lations. Careful statistical analyses were made of reliability with-
in our various clinical populations and in our normal control sub-
jects, by using where appropriate (a) retest coefficients, (b) mea-
sures of internal consistency, and (c) analysis of variance of
components due to measurement error and systematic variance
[109—113]. (See Table 1 of Appendix.)
Although conclusions must be stated with considerable cau-
tion in view of the small sample sizes, the evidence was encour-
aging: the coefficients of various kinds ranged from around 0.70
to above 0.90. More important than the statistical evidence, how-
ever, are two further factors regarding test reliability: (1) the
neurobehavioral measures that survived these investigations
were effective in differentiating some or all of our treatment
groups from one another and from the control subjects; and (2)
aside from several that were used on a provisional and explor-
atory basis, the neurobehavioral measures were either modeled
directly after traditional indicators of various aspects of mental
alertness or were highly analogous to those. Since traditional
measures of reaction time, recognition memory, vigilance,
tasks requiring sustained attention, and other indicators of adapt-
ive competence are known to be reasonably reliable in most pop-
ulations, it was relatively safe for us to assume that they would
be satisfactorily reliable in our research context also.
Validity of neurobehavioral measures. As should be done in
most research projects, we selected or constructed measures for
which considerable evidence previously had been gathered re-
garding both reliability and validity. Although several were
rather exploratory, the major instruments which were most ex-
tensively studied had extensive "pedigrees" of usefulness in
measuring what they are purported to measure. The reader is
referred especially to discussions of measurement methods con-
cerning various aspects of mental alertness in Adams [17], Anas-
tasi [18], Buros [19], and Nunnally [109, 114, 115]. In addition to
relying heavily on evidence from such previous studies, we also
attended to evidence in our ongoing investigations regarding the
validity of our measuring instruments:
Our initial criterion for validity of these measures is that they
should vary with the clinical events of interest to us in reasonable
coherence with the known expected clinical changes in these re-
spective circumstances. Thus, in patients with end-stage renal
disease, the scores and changes in scores upon repeated testing
should reflect impairments which (a) vary directly with the de-
gree of renal failure, (b) improve with onset of maintenance dial-
ysis, and (c) improve further following successful renal trans-
plantation. They did so.
Other criteria of validity were also examined: (1) Predictive
validity of neurobehavioral tests. In the absence of an estab-
lished, quantitative criterion or reference standard for clinical
uremic symptoms with which tests results could be correlated,
predictive validity was achieved in terms of "functional relations
between an instrument (test measure) and events occurring be-
fore, during, and after the instrument is applied" [109], that is,
that each test score in fact represented some measured contem-
poraneous encephalic activity. The specific time frame in which
we investigated predictive validity is usually referred to as con-
current validity, meaning the empirical relationship between a
predictor instrument and a known, current state of affairs, for
example, as in using a test of brain damage to distinguish be-
tween patients who do have brain damage and those who do not
have brain damage. Thus, to the extent to which our measures
demonstrated in a direct, statistical manner their ability to dif-
ferentiate among our clinical samples and differentiate our clini-
cal samples from our normal control subjects, they exhibited pre-
dictive validity. (2) Content validity of neurobehavioral tests.
Content validity depends upon "appeals to reason regarding the
adequacy with which important content has been sampled" by
the test measures and "the adequacy with which the content has
been cast in the form of test items" [109]. The "appeal to rea-
son" in these studies is that: (a) the EEG is generally regarded to
reflect states of consciousness, alertness (for example, vs.
drowsiness or sleep), and certain neuromuscular events (for ex-
ample, seizures) and to respond to afferent somatosensory stimu-
li (for example, evoked cortical potentials, the VER), despite
lack of precise knowledge of the origin or the functional (opera-
tional) significance of the various EEG wave forms or character-
istic frequencies; (b) decision-making, short-term memory, and
sustained attention are cognitive processes, or aspects of cogni-
tion; and that (c) cognitive, somatosensory, and neuromuscular
(and autonomic) impairments are in fact the principal categories
into which the characteristic symptoms of clinically overt uremia
may be classified [38]. The lack of identity is noted, for example,
between specific test behaviors or EEG wave characteristics and
the integrated, complex illness behaviors which we witness at
the patient's bedside. Thus, to the extent to which we have ade-
quately sampled the most salient item content pertaining to vari-
ous aspects of mental alertness, we can claim a degree of content
validity for our battery of measuring instruments.
Construct validity of neurobehavioral tests. We are not, how-
ever, ultimately interested in EEG wave forms, choice reaction
times, or in memory or vigilance errors themselves, but in the
much more abstract construct: brain or CNS function in uremia
and its subsets, electrophysiologic functions and cognitive fun-
tions. A provisional name for the measurable correlates of
the latter CNS functions is general mental alertness which is ob-
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served to be markedly impaired in symptomatic uremia. The im-
plied hypothesis is that the test measures bear a relevant, in-
dicator relationship to the more abstract constructs of interest to
us.
As documented in Results, we have proceeded in all three as-
pects of the process by which measures of our theoretical con-
struct may be explicated [1091: (1) "The domain of observables"
has been at least provisionally outlined to include the neurobe-
havioral manifestations which characterized clinically overt ure-
mia in patients with renal failure. Moreover, we have postulated
that measures of neurobehavioral function will demonstrate im-
pairments in patients with renal failure and that these impair-
ments will vary in response to the degree of renal failure, to dial-
ysis, and to transplantation. (2) A degree of intercorrelation or
"internal consistency" exists within the test battery of the mea-
sures in the three clinical situations specified, that is, that the
"observables 'go together' in empirical investigations" 1109]. (3)
The measures "behave as expected" [109] in accord with the
common clinical observations that patients with end-stage renal
disease tend to have more and more severe uremic symptoms at
higher grades of renal failure, improve symptomatically on main-
tenance hemodialysis, and improve still further if renal trans-
plantation is successful.
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